tACS Alters EEG Microstates in DoC

July 10, 2026 updated by: eren toplutas, Istanbul Medipol University Hospital

Transcranial Alternating Current Stimulation Is Associated With Changes in EEG Microstate Dynamics in Disorders of Consciousness

Disorders of consciousness (DoC), including unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS), remain difficult to diagnose at the bedside. Electroencephalography (EEG) microstate analysis provides a high-temporal-resolution approach for characterizing large-scale resting-state brain dynamics, and its application in neuromodulation studies remains under investigation.

This study is designed to investigate the effects of a single 20-minute session of 40 Hz transcranial alternating current stimulation (tACS) applied over the bilateral dorsolateral prefrontal cortex (DLPFC) on resting-state EEG microstate parameters in patients with DoC. Participants undergo resting-state EEG recordings immediately before and after a 2 mA, 40 Hz bilateral DLPFC tACS session. EEG microstate maps (A-G) are identified by back-fitting to individual recordings, and microstate parameters including mean duration, occurrence, coverage, and global explained variance (GEV) are calculated. Behavioral assessments are performed using the Coma Recovery Scale-Revised (CRS-R) and the Simplified Evaluation of CONsciousness Disorders (SECONDs). The study aims to characterize changes in EEG microstate dynamics following tACS and to examine their associations with behavioral measures of consciousness.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bağcılar
      • Istanbul, Bağcılar, Turkey (Türkiye)
        • Medipol Mega University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Medically stable at the time of assessment.
  • No administration of sedative or hypnotic medication within the previous 24 hours.
  • Preserved wakefulness (spontaneous or elicited by stimulation) with reduced or absent awareness, consistent with Unresponsive Wakefulness Syndrome (UWS) or Minimally Conscious State (MCS).
  • Diagnosis confirmed by an experienced neurologist using repeated clinical assessments with the Coma Recovery Scale-Revised (CRS-R) and the Simplified Evaluation of CONsciousness Disorders (SECONDs) performed on different days and at different times during periods of wakefulness.

Exclusion Criteria:

  • Acute phase of brain injury (within the first 28 days after injury).
  • Administration of sedative or hypnotic medication within the previous 24 hours.
  • Medical instability (e.g., active infection or hemodynamic instability).
  • Epileptic seizures uncontrolled despite anticonvulsant therapy.
  • Serious systemic illnesses that could affect the level of consciousness (e.g., sepsis or end-stage organ failure).
  • Brain death or coma without any evidence of wakefulness.
  • A previous history of developmental disorders, major neurological disorders, or severe psychiatric disorders associated with significant functional impairment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Disorders of Consciousness and TACS
We evaluated the effect of a single 20-minute session of 40 Hz transcranial alternating current stimulation (tACS) over the bilateral dorsolateral prefrontal cortex (DLPFC) on resting-state EEG microstate parameters in DoC and their relationships with behavioral consciousness scores.
After completion of the first 20-minute resting-state EEG, tACS was applied using a Neurosoft / Neurostim device. Stimulation was performed at the 40 Hz gamma frequency, with two stimulation electrodes placed bilaterally over the DLPFC. According to the international 10-20 system, this placement corresponded to the F3 (left DLPFC) and F4 (right DLPFC) electrode positions. The stimulation lasted 20 minutes, and a constant current intensity of 2 mA was used throughout. The current was delivered as a sinusoidal waveform without phase shifting or modulation. The electrodes were sponge-based pads measuring 5 × 7 cm each. To improve conductivity and ensure homogeneous skin contact, the sponge electrodes were moistened with 0.9% isotonic sodium chloride (saline). Electrodes were secured to the skin to optimize contact quality and homogenize current distribution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting-State EEG Microstate Parameters
Time Frame: Baseline and immediately after the 20-minute tACS session.
EEG recordings were obtained in different settings according to the patient's physical condition. From every individual, a total of 20 minutes of resting-state EEG was obtained. EEG recordings were performed using a Neurosoft NEURON-SPECTRUM-4 device and Neuron-Spectrum.NET software. Recordings were obtained from 19 electrode channels positioned according to the international 10-20 system: Fp1, Fp2, F7, F3, Fz, F4, F8, T7, C3, Cz, C4, T8, P7, P3, Pz, P4, P8, O1, O2. Data were digitized at a sampling rate of 500 Hz. Resting-state electroencephalography (EEG) microstate parameters, including mean duration, occurrence, coverage, and global explained variance (GEV) of microstate classes A-G, derived from 19-channel scalp EEG recordings using microstate analysis.
Baseline and immediately after the 20-minute tACS session.
Coma Recovery Scale-Revised (CRS-R)
Time Frame: Baseline and immediately after the 20-minute tACS session.
The CRS-R is a standardized clinical assessment tool used to evaluate the level of consciousness in patients with disorders of consciousness. It consists of six subscales: auditory, visual, motor, oromotor/verbal, communication, and arousal. The total score ranges from 0 to 23, with higher scores indicating a higher level of consciousness. Diagnostic interpretation is based not only on the total score but also on the highest behavioral responses observed within each subscale.
Baseline and immediately after the 20-minute tACS session.
Simplified Evaluation of CONsciousness Disorders (SECONDs)
Time Frame: Baseline and immediately after the 20-minute tACS session.
The SECONDs is a brief bedside assessment designed for the rapid evaluation of patients with disorders of consciousness. It assesses arousal and behavioral responses to simple commands and environmental stimuli. The total score ranges from 0 to 8, with higher scores indicating a better level of consciousness. It is a practical tool for screening and longitudinal clinical monitoring.
Baseline and immediately after the 20-minute tACS session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2020

Primary Completion (Actual)

December 12, 2021

Study Completion (Actual)

September 12, 2024

Study Registration Dates

First Submitted

July 1, 2026

First Submitted That Met QC Criteria

July 10, 2026

First Posted (Actual)

July 13, 2026

Study Record Updates

Last Update Posted (Actual)

July 13, 2026

Last Update Submitted That Met QC Criteria

July 10, 2026

Last Verified

December 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 10840098-772.02-47943

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data will be available upon reasonable request to the corresponding author for scientifically sound research purposes.

IPD Sharing Time Frame

Unending

IPD Sharing Access Criteria

Requests for de-identified individual participant data should be submitted to the corresponding author. Requests will be reviewed for scientific merit and compliance with ethical and institutional requirements. A data-sharing agreement may be required before data are provided.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.